Talks and panel on programmable medicine
On November 2, 2022, during MIT Technology Review’s EmTech conference, Dr. Omar Costilla Reyes attended an exceptional set of talks and a panel on the future of medicine by Kiran Musunuru and Noubar Afeyan. He wrote that it was very inspiring to see this happening and thanked the magazine and its biomedicine editor Antonio Regalado for organizing it. The conference program lists Afeyan, founder and chief executive of Flagship Pioneering, for a session titled “Reshaping Human Health” that afternoon, and the photograph on this page shows its opening slide. MIT Technology Review later reported that Musunuru, a cardiologist, spoke with Regalado about gene editing to treat heart disease, including a clinical trial testing whether editing a cholesterol-regulating gene could help prevent future heart-disease deaths.
What programmable medicine means
Programmable medicine refers to therapies designed from information, so that their instructions can be written and changed rather than discovered molecule by molecule. In an mRNA vaccine, for example, the active ingredient is a genetic sequence that tells cells which protein to make, so a new target can be addressed largely by rewriting the sequence. Gene editing goes a step further by changing a sequence in the patient’s own DNA. The EmTech session description linked the pandemic to renewed attention on these approaches and asked how digital biology might change vaccine development and the understanding of illness.
Interest as a research area
Dr. Costilla Reyes said the talks made him excited to explore this area of research. The theme returned in December 2024, when he hosted Moderna’s chief executive, Stéphane Bancel, for a conversation on the future of medicine at MIT Sloan.